TMCnet News
Cue Biopharma Appoints Bethany Mancilla as Chief Business Officer and Senior Vice PresidentCAMBRIDGE, Mass., July 24, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ:CUE) a next-generation immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today the appointment of Bethany Mancilla as Chief Business Officer and Senior Vice President, Corporate Development and Strategic Planning. Mancilla, who most recently served as Vice President, Business Development at Amgen, brings extensive experience in immuno-oncology and more than 20 years of broad, multi-national business development experience to Cue Biopharma. Mancilla will oversee corporate strategy, financing initiatives, and business development, including the implementation of strategic collaborations based on Cue Biopharma’s Immuno-STATTM platform. “Bethany is perfectly suited to maximize the opportunities we see arising from our Immuno-STAT platform,” said Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer of Cue Biopharma. “She has worked with a spectrum of companies that are developing targeted immune-modulating therapies, providing Bethany with deep expertise in this area. As a key member of our Senior Management Team, Bethany will further enhance Cue Biopharma’s corporate development and strategic positioning. On behalf of our board and management team, we welcome Bethany and look forward to her insights and contributions.” “Immunotherapy research and development has made tremendous progress over the past five years, but there remains a significant need for better and safer treatments, opening the door for novel treatments for cancer, autoimmune and chronic infectious diseases. Cue Biopharma’s Immuno-STAT platform offers the potential for an off-the-shelf immunotherapy approach for a wide variety of indications,” said Mancilla. “The platform has already delivered its first clinical candidate, and I am excited to join the Cue Biopharma team to help advance and expand the potential value of the platform and to drive opportunities for patients and shareholders.” Mancilla has more than 20 years of strategic biopharmaceutical business development experience defining, identifying, negotiating, maintaining and expanding drug discovery and development collaborations. Prior to joining Cue Biopharma, she served as Vice President, Business Development at Amgen, where she led a transaction team responsible for assessing and executing product licensing, co-development, co-commercialization, profit sharing, equity investment, joint venture, mergers and acquisition opportunities to optimize Amgen’s pipeline. Before joining Amgen, Mancilla was Vice President, Business Development and Alliance Management at Micromet where she was responsible forestablishing partnerships in the U.S. and creating an alliance-management capability. Prior to joining Micromet, she held business development roles of increasing responsibility at Pharmathene, Gene Logic, Lark Technologies, Sennes Drug Innovations, and BCM Technologies. Mancilla received her BA from the University of Colorado, Boulder and her MBA from the University of Houston, Texas. About Cue Biopharma We believe our selective biologics allow us to target antigen-specific T cell populations in a variety of indications using a peptide – MHC complex for delivering T cell modulating effectors, such as IL-2. Once a biologic has been optimized, our approach offers the potential for readily exchanging peptides to target different T cell populations and indications using previously-validated drug frameworks developed from the Immuno-STATTM platform. This flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost-efficiently than current industry standard timelines and costs. Headquartered in Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board (SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology. For more information, visit www.cuebio.com. Forward-Looking Statements Investor Contact: Media Contact: |